<DOC>
	<DOCNO>NCT01127490</DOCNO>
	<brief_summary>The purpose study examine characteristic nerve small vein skin people fibromyalgia . The investigator use information identify possible process skin may help explain people feel pain relief study drug ( duloxetine ) others . Duloxetine affect certain chemical brain call neurotransmitter . An abnormality chemical think related fibromyalgia . Duloxetine selective serotonin norepinephrine reuptake inhibitor ( SNRI ) , similar drug use treatment depression . Duloxetine approve sale United States Food Drug Administration ( FDA ) treatment fibromyalgia .</brief_summary>
	<brief_title>Study Assess Mechanisms Peripheral Tissue Innervation Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Female age 1870 Fulfill ACR criterion FMS ( wide spread pain least 3 month pain least 11 18 tender point site . VAS score great 40mm Screening Randomization Visits History clinically significant liver disease , serious peripheral vascular disease , blood clot disorder , medical condition felt exclusionary investigator Allergy lidocaine Unwillingness sign inform consent reason investigator feel subject complete study . Women pregnant , breastfeed try become pregnant Active cancer within previous two year except treat basal cell carcinoma skin Presence dermatological neurological condition could interfere interpretation skin biopsy QST Coexisting condition produce chronic widespread pain Presence uncontrolled severe depression Patients pending Worker 's Compensation , worker 's Compensation , ongoing litigation disability claim due fibromyalgia source pain , currently receive monetary compensation result . Presence uncontrolled narrowangle glaucoma</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>